Dexrazoxane (icrf)

CAS 24584-09-6

About the API

Systematic name (S)-4,4'-(1-methyl-1,2-ethanediyl)bis-2,6-piperazinedione
Trade name(s) Zinecard, Totect, Savene, Cardioxane, Cyrdanax, Cyathus, Enaxozar, Procard, Dexrazoxane
Molecular Formula C11H16N4O4
Molecular Weight 268.28 g/mol
Physical properties White to off-white or pale pink lyophilized powder or cake
Therapeutic category Cardiovascular
Available formulations Injectables
Regulations EU DMF Flag EU DMF Japan DMF Flag Japan DMF US DMF Flag US DMF

General Information

Dexrazoxane is a drug for serious side effects – cardiomyopathy and extravasation – caused by certain anticancer drugs of the anthracycline family.

Specifically, it is used to reduce the incidence and severity of cardiomyopathy (disease of the heart muscle) in adult patients with metastatic breast cancer receiving doxorubicin or epirubicin therapy. In the United States this indication is narrower – applying to women treated with doxorubicin. It should not be used with the initiation of therapy, but rather after a cumulative doxorubicin dose of 300 mg/ m2 or 540 mg/m2 epirubicin, in patients who will continue to receive these drugs.

In addition, dexrazoxane is used for the treatment of extravasation (the leaking of injected medicine from blood vessels into tissue) in patients receiving intravenous anthracycline chemotherapy. Studies show that it significantlyreduces the need for surgical intervention. The first of three infusions is administered as soon as possible within the first six hours after extravasation.